Document is current
Any future updates will be listed below
-
Authors
Akinsanya, Karen
AlQuraishi, Mohammed
Boija, Ann
Chodera, John
CichoĊska, Anna
Ghassemi, Marzyeh
Head, Martha
Jin, Wengong
Kibbe, Warren A.
Krogan, Nevan
LeVine, Michael V.
Moult, John
Stuart, Lynda
Tourassi, Georgia
Zou, James
Barzilay, Regina
Elemento, Olivier https://orcid.org/0000-0002-8061-9617
- License Information
-
More Information
Article History
First Online: 19 August 2025
Competing interests
: A.B. is an employee and shareholder of Dewpoint Therapeutics and holds multiple patents related to the work discussed in this Comment. A.C. is an employee and stock option holder at Harmonic Discovery. K.A. is stock holder in Schrodinger and Nautilus Biotechnology. M.A. is a member of the scientific advisory boards of Cyrus Biotechnology, Deep Forest Sciences, Nabla Bio, Oracle Therapeutics, and Achira. O.E. is co-founder and stock holder in Volastra Therapeutics, holds stock in Freenome, serves as a member of the scientific advisory board (SAB) and holds stock options in Owkin, Harmonic Discovery, and Exai, is an SAB member for Canary Biosciences, and is receiving or has received funding from Eli Lilly, J&J/Janssen, Sanofi, AstraZeneca, and Volastra. J.C., M.G., M.H., W.J., W.A.K., N.K., M.V.L., J.M., L.S., G.T., J.Z., and R.B. declare no competing interests.
